AzTrials
AzTrials

Smoking (Tobacco) AddictionPhase 3PREVENTNCT05102123

PeRiopEratiVE SmokiNg CessaTion Trial

A Phase 3 study testing Cytisine and Video Messaging in people with Smoking (Tobacco) Addiction and Smoking Cessation, run by Population Health Research Institute at 4 sites in Canada.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

PREVENT is a multicentre, 2x2 factorial, randomized clinical trial that aims to determine the effect of cytisine versus placebo, as well as the effect of video messaging to support smoking cessation versus standard of care in perioperative patients. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Cytisine and Video Messaging
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
1,720 participants
Where
4 sitesCanada
Study dates
15 Jan 2024to 1 Jan 2027
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • are ≥18 years of age
  • are scheduled to undergo surgery within 28 days
  • are a current smoker and not currently using any smoking cessation treatment and,
  • have a smart mobile phone with an active, up to date data plan and with internet access
  • provide informed consent to participate.

Who cannot join

  • are pregnant or breastfeeding or expecting to become pregnant during the study follow-up period
  • are deemed unreliable for study procedures or follow-up
  • have a documented allergic reaction to cytisine, or its components (non-medicinal ingredients) or to the non-medicinal ingredients of the placebo.
  • had myocardial infarction, unstable angina, or stroke/transient ischemic attack within the preceding 2 weeks.
  • will have surgery with expected nil intake by mouth for 2 or more days
  • have previously participated in PREVENT
  • have a known diagnosis of untreated pheochromocytoma; Schizophrenia/bipolar psychiatric illness and currently psychotic; currently having suicidal ideation or risk of suicide as determined by the site physician, known history of moderate to severe depression; currently uncontrolled severe hypertension (≥180/120 mmHg) despite treatment; known history of uncontrolled hyperthyroidism (thyrotoxicosis), severe renal impairment i.e., creatinine clearance of less than 30 ml per minute (Cockcroft- Gault equation) or receiving long-term dialysis, or known diagnosis of severe liver disease as determined by the site physician or documented in the clinical history.

Trial locations and contacts

4 sites in 1 country.

Canada4 sites
  • Hamilton General Hospital

    Hamilton, Ontario, L8L 2X2

  • Juravinski Cancer Centre

    Hamilton, Ontario, L8V 5C2

  • Kingston Health Science Centre with its research institute Kingston General Health Research Institute

    Kingston, Ontario, K7L 3N6

  • Lawson Health Research Institute: London Health Sciences Centre Research Inc. and the Lawson Research Institute

    London, Ontario, N6C 2R5

Other trials in Canada

About this study

PREVENT is a multicentre, 2x2 factorial, randomized clinical trial that aims to determine the effect of cytisine versus placebo, as well as the effect of video messaging to support smoking cessation versus standard of care in perioperative patients. This trial aims to investigate the effects of cytisine and text messaging on 6-month continuous abstinence rates. PREVENT will also assess secondary outcomes at 30 days, 56 days and 6 months post-randomization: 7-day point prevalence abstinence, urge to smoke, time to first lapse, time to relapse, number of cigarettes smoking if still smoking, pulmonary complications, vascular complications, wound and infectious complications, stroke, time in hospital and acute hospital care.

Being tested
Cytisine, Video Messaging
Medical subject headings
Smoking, Behavior, Addictive, Smoking Cessation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CytisineDrug

    Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation

  • Video MessagingBehavioural

    Supportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period.

Study groups in NCT05102123
Study groupRoleWhat they receive
Cytisine and Video MessagingExperimentalAdministration of cytisine (pharmaceutical support) to patients on a set dose schedule with behavioural support through video messaging.
Receives: Drug: Cytisine; Behavioral: Video Messaging
Placebo and Video MessagingPlacebo comparatorAdministration of placebo (inactive drug) to patients on a set dose schedule with behavioural support through video messaging.
Receives: Behavioral: Video Messaging
Cytisine and No Video MessagingActive comparatorAdministration of cytisine (pharmaceutical support) to patients on a set dose schedule with behavioural support according to standard care such as a phone number for a self-help line.
Receives: Drug: Cytisine
Placebo and No Video MessagingNo interventionAdministration of placebo (inactive drug) to patients on a set dose schedule behavioural support according to standard care such as a phone number for a self-help line.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Smoking Cessation

    complete abstinence (smoking not more than 5 cigarettes) beginning on day 5 post randomization and lasting until the assessment at 6 months post-randomization with biochemical verification for those who report abstinence, using exhaled breath carbon monoxide (cut-off <10 parts per million [ppm]) measured with a carbon monoxide (CO) monitor

    Measured: 6 months

Secondary outcomes (18)
  1. 7-day point-prevalence abstinence at 30 days

    Self-report of not smoking cigarettes [not even a puff] in the 7 days before the 30-day follow-up

    Measured: 30 days

  2. 7-day point-prevalence abstinence at 56 days

    Self-report of not smoking cigarettes [not even a puff] in the 7 days before the 56-day follow-up

    Measured: 56-days

  3. 7-day point-prevalence abstinence at 6-months

    Self-report of not smoking cigarettes [not even a puff] in the 7 days before the 6-month follow-up

    Measured: 6-months

  4. Urge to smoke

    urge to smoke using the Mood and Physical Symptoms Scale [MPSS] at baseline and 6 months; a higher score indicates a stronger urge to smoke; To assess the effect of abstinence calculate the change from baseline (just prior to stopping smoking) to the post-abstinence follow-up point for items 1 to 7 and 10 to 12, and take the raw scores for items 8 and 9

    Measured: baseline and 6-months

  5. Number of cigarettes smoked daily if still smoking

    Number of cigarettes smoked daily if still smoking

    Measured: 30 days, 56 days and 6 months

  6. Time to first lapse

    Time to first cigarette smoked after the initial quit, even a single puff

    Measured: 6 months

  7. Time to relapse

    Time to return to regular smoking for three or more concurrent days after a period of abstinence.

    Measured: 6 months

  8. 6 month continuous abstinence rate

    Complete abstinence (smoking not more than 5 cigarettes) beginning on the quit date and lasting until the assessment at 6 months post-randomization with biochemical verification for those who report abstinence, using exhaled breath carbon monoxide (cut-off <10 ppm) measured with a carbon monoxide (CO) monitor.

    *Cigarettes smoked within 5 days of randomization will be discounted.

    Measured: 6-months

  9. Wound complications

    Seroma- wound drainage or repeated dressings required; Wound dehiscence or delayed wound healing

    Measured: 6 months

  10. Infectious complications

    Infection - defined as a pathologic process caused by the invasion of normally sterile tissue, fluid, or body cavity by pathogenic or potentially pathogenic organisms.

    Surgical site infection- An infection that occurs within 30 days after surgery and involves the skin, subcutaneous tissue of the incision (superficial incisional), or the deep soft tissue (e.g., fascia, muscle) of the incision (deep incisional).

    Sepsis- Based on the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Sepsis requires a quick Sequential Organ Failure Assessment (qSOFA) Score ≥2 points due to infection. The qSOFA includes the following items and scoring system: 1. altered mental status (1 point); 2. systolic blood pressure ≤100 mm Hg (1 point); and 3. respiratory rate ≥22 breaths per minute (1 point).

    Measured: 6 months

  11. Respiratory complications

    Pneumonia - defined as an acute infection of the pulmonary parenchyma that is associated with at least one sign or symptom of lower respiratory acute infection (e.g., cough, pleuritic chest pain) or acute systemic illness (e.g., fever, chills, confusion, hypoxemia); accompanied by the presence of an acute infiltrate/consolidation on a chest radiograph or auscultatory findings consistent with pneumonia (such as crackles and/or localized rales) for which there is no other explanation.

    Respiratory insufficiency requiring ventilatory support - Patient intubated or put on bilevel positive airway pressure (BiPAP).

    Measured: 6 months

  12. Non-fatal Myocardial infarction

    according to the 4th universal definition

    Measured: 6 months

  13. Number of Patients with Proximal venous thrombo-embolism

    The diagnosis of PE requires any one of the following:

    1. A high probability ventilation/perfusion lung scan,
    2. An intraluminal filling defect of a segmental or larger artery on a helical computerized tomography (CT) scan,
    3. An intraluminal filling defect on pulmonary angiography, or
    4. A positive diagnostic test for deep venous thrombosis A. Non-diagnostic ventilation/perfusion lung scan B. Non-diagnostic helical CT scan.

    The diagnosis of proximal DVT (leg or arm) requires:

    1. Thrombosis involving the popliteal vein or more proximal veins for leg DVT and axillary or more proximal veins for arm DVT, AND
    2. Evidence of vein thrombosis by any one of the following:
    3. A persistent intraluminal filling defect on contrast venography, 2. Non-compressibility of one or more venous segments on B mode compression ultrasonography, or 3. A clearly defined intraluminal filling defect on contrast enhanced computed tomography.

    Measured: 6 months

  14. Stroke

    Stroke is defined as either: 1. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting ≥24 hours or leading to death; or 2. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting <24 hours with positive neuroimaging consistent with a stroke.

    Measured: 6 months

  15. Non-fatal cardiac arrest

    Nonfatal cardiac arrest is defined as successful resuscitation from either documented or presumed ventricular fibrillation, sustained ventricular tachycardia, asystole, or pulseless electrical activity requiring cardiopulmonary resuscitation, pharmacological therapy, or cardiac defibrillation.

    Measured: 6 months

  16. Death

    The definition of death is all cause mortality.

    Measured: 6 months

  17. Length of hospital stay

    Defined as time of hospital admission to time of discharge from hospital after index surgery.

    Measured: time of hospital admission to time of discharge for surgical stay

  18. Acute hospital care since discharge

    Acute-hospital care is a composite outcome of hospital re-admission (patient admission to an acute-care hospital) and emergency department visit (patient visit to an emergency department, which includes urgent-care centre visit).

    Measured: after hospital discharge for the study surgery to 6-month follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Nov 2021
  2. Study start15 Jan 2024
  3. Primary completion1 Jul 2026 (estimated)
  4. Study completion1 Jan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Factorial
Model description
2x2 factorial
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
1,720 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05102123
Sponsor's protocol ID
2022_09_01
Acronym
PREVENT
Status last verified
Oct 2024
First submitted
19 Oct 2021
Last updated
3 Oct 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The Population Health Research Institute (PHRI) is the sponsor of this trial. The PHRI believes the dissemination of clinical research results is vital and sharing of data is important. PHRI prioritizes access to data analyses to researchers who have worked on the trial for a significant duration, have played substantial roles, and have participated in raising the funds to conduct the trial. PHRI balances the length of the research study, and the intellectual and financial investments that made it possible with the need to allow wider access to the data collected. Data will be disclosed only upon request and approval of the proposed use of the data by a Review Committee.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Cytisine and Video Messaging in people with Smoking (Tobacco) Addiction and Smoking Cessation, run by Population Health Research Institute at 4 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 3 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Smoking Cessation (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in